Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease

Clinical trial NCT07571161 · RECRUITING

Trial details

NCT number: NCT07571161
Sponsor: Eli Lilly and Company
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Alzheimer Disease

Start date: 2026-04-30
Primary completion: 2030-04-01
Enrollment: 140

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.